2019 | 2020 | 2021 | 2022 | 2023e | |
---|---|---|---|---|---|
Umsatz | 236,09 | 231,69 | 235,84 | 237,62 | 307,63 |
Bruttoergebnis vom Umsatz | 95,10 | 78,76 | 33,41 | 36,58 | 51,68 |
EBITDA | 28,16 | 12,14 | 20,18 | 29,25 | 36,70 |
EBIT | 18,15 | 4,08 | 13,98 | 21,32 | 26,41 |
Ergebnis vor Steuer | 12,19 | -77,20 | 12,33 | 9,91 | 20,85 |
Ergebnis nach Steuern | 8,77 | -77,27 | 8,28 | 6,63 | 10,76 |
2019 | 2020 | 2021 | 2022 | 2023e | |
---|---|---|---|---|---|
Aktiva | 384,20 | 292,17 | 291,92 | 438,44 | 448,52 |
Umlaufvermögen | 137,93 | 106,31 | 113,21 | 150,84 | 132,65 |
Summe Anlagevermögen | 246,27 | 185,87 | 178,71 | 287,60 | 315,87 |
Passiva | 384,20 | 292,17 | 291,92 | 438,44 | 448,52 |
Summe kurzfristige Verbindlichkeiten | 72,87 | 84,88 | 82,21 | 89,00 | 93,55 |
Summe langfristige Verbindlichkeiten | 119,01 | 95,01 | 88,19 | 107,31 | 103,01 |
Summe Fremdkapital | 191,88 | 179,89 | 170,40 | 196,31 | 196,56 |
Bilanzielles Eigenkapital | 192,32 | 112,28 | 121,52 | 235,82 | 242,85 |
2019 | 2020 | 2021 | 2022 | 2023e | |
---|---|---|---|---|---|
Cashflow | 1,16 Mio. | 5,29 Mio. | 27,46 Mio. | 19,03 Mio. | 17,75 Mio. |
2023e | |
---|---|
0,01 | Dividende je Aktie |
Datum | Unternehmen | Termin |
---|---|---|
10.05.2024 | Dividendentermin | |
10.05.2024 | Dividendentermin | |
13.05.2024 | Dividendentermin | |
13.05.2024 | Dividendentermin | |
14.05.2024 | Dividendentermin | |
14.05.2024 | Dividendentermin | |
15.05.2024 | Dividendentermin | |
16.05.2024 | Dividendentermin |
2023e | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | |
---|---|---|---|---|---|---|---|
3,81 % | Dividendenrendite | - | - | - | - | - | |
10,50 | Kurs-Gewinn-Verhältnis (KGV) | 13,33 | -0,57 | 12,21 | 25,52 | - | 29,30 |
7 | Kurs-Cash-Flow-Verhältnis (KCV) | 99,95 | 8,50 | 3,05 | 8,51 | - | |
0,58 | Kurs-Buchwert-Verhältnis (KBV) | 0,67 | 0,40 | 0,72 | 0,73 | - | |
0,47 | Kurs-Umsatz-Verhältnis (KUV) | 0,54 | 0,19 | 0,36 | 0,71 | - | |
0,45 | Umsatz je Aktie | 0,74 | 0,89 | 0,67 | 0,36 | - | |
0,03 | Cashflow je Aktie | 0,00 | 0,02 | 0,08 | 0,03 | - | |
Umsatzrentabilität | 3,72 % | - | 3,51 % | 2,79 % | 3,50 % | ||
Eigenkapitalrendite | 4,56 % | - | 6,81 % | 2,81 % | 4,43 % | ||
Anlageintensität | 64,00 % | 64,00 % | 61,00 % | 66,00 % | 70,00 % | ||
Arbeitsintensität | 36,00 % | 36,00 % | 39,00 % | 34,00 % | 30,00 % | ||
Gesamtrendite | 2,28 % | - | 2,84 % | 1,51 % | 2,40 % | ||
Eigenkapitalquote | 50,06 % | 38,43 % | 41,63 % | 53,79 % | 54,14 % | ||
Fremdkapitalquote | 49,94 % | 61,57 % | 58,37 % | 44,78 % | 43,82 % | ||
Verschuldungsgrad | 99,77 % | 160,21 % | 140,23 % | 83,25 % | 80,94 % | ||
Working Capital in Mio. | 65,06 | 21,43 | 31,00 | 63,46 | 39,10 | ||
Deckungsgrad A | 78,09 % | 60,41 % | 68,00 % | 82,00 % | 76,88 % | ||
Deckungsgrad B | 113,96 % | 104,47 % | 112,99 % | 107,52 % | 98,28 % | ||
Deckungsgrad C | 94,28 % | 83,51 % | 87,68 % | 91,20 % | 81,79 % |
2019 | 2020 | 2021 | 2022 | 2023e | |
---|---|---|---|---|---|
Aktien im Umlauf in Mio. | 320,06 | 259,80 | 353,88 | 665,59 | 681,68 |
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. The company was incorporated in 1994 and is based in Mt Waverley, Australia.
Adresse | PIMCO Investments LLC distributor |
Telefon | 888-877-4626 |
Internet | https://www.paragoncare.com.au |